| MeSH term | MeSH ID | Detail |
|---|---|---|
| Amenorrhea | D000568 | 4 associated lipids |
| Amputation, Traumatic | D000673 | 2 associated lipids |
| Anemia | D000740 | 21 associated lipids |
| Anemia, Aplastic | D000741 | 6 associated lipids |
| Anemia, Hemolytic | D000743 | 4 associated lipids |
| Anemia, Hemolytic, Autoimmune | D000744 | 5 associated lipids |
| Anemia, Refractory | D000753 | 3 associated lipids |
| Anemia, Refractory, with Excess of Blasts | D000754 | 2 associated lipids |
| Aneurysm, Dissecting | D000784 | 2 associated lipids |
| Angiolymphoid Hyperplasia with Eosinophilia | D000796 | 1 associated lipids |
tacrolimus
Tacrolimus is a lipid of Polyketides (PK) class. Tacrolimus is associated with abnormalities such as Renal glomerular disease. The involved functions are known as inhibitors, Fungicidal activity, Metabolic Inhibition, Excretory function and Dephosphorylation. Tacrolimus often locates in Hepatic, Mitochondrial matrix and Inner mitochondrial membrane. The associated genes with Tacrolimus are RHOA gene and BGN gene.
Cross Reference
Introduction
To understand associated biological information of tacrolimus, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.
What diseases are associated with tacrolimus?
tacrolimus is suspected in Renal glomerular disease, Candidiasis, Mycoses, PARKINSON DISEASE, LATE-ONSET, Morphologically altered structure, Skin Diseases, Infectious and other diseases in descending order of the highest number of associated sentences.
Related references are mostly published in these journals:
| Disease | Cross reference | Weighted score | Related literature |
|---|
Loading... please refresh the page if content is not showing up.
Possible diseases from mapped MeSH terms on references
We collected disease MeSH terms mapped to the references associated with tacrolimus
PubChem Associated disorders and diseases
What pathways are associated with tacrolimus
There are no associated biomedical information in the current reference collection.
PubChem Biomolecular Interactions and Pathways
Link to PubChem Biomolecular Interactions and PathwaysWhat cellular locations are associated with tacrolimus?
Visualization in cellular structure
Associated locations are in red color. Not associated locations are in black.
Related references are published most in these journals:
| Location | Cross reference | Weighted score | Related literatures |
|---|
Loading... please refresh the page if content is not showing up.
What functions are associated with tacrolimus?
Related references are published most in these journals:
| Function | Cross reference | Weighted score | Related literatures |
|---|
What lipids are associated with tacrolimus?
Related references are published most in these journals:
| Lipid concept | Cross reference | Weighted score | Related literatures |
|---|
Loading... please refresh the page if content is not showing up.
What genes are associated with tacrolimus?
Related references are published most in these journals:
| Gene | Cross reference | Weighted score | Related literatures |
|---|
What common seen animal models are associated with tacrolimus?
There are no associated biomedical information in the current reference collection.
NCBI Entrez Crosslinks
All references with tacrolimus
Download all related citations| Authors | Title | Published | Journal | PubMed Link |
|---|---|---|---|---|
| Jain A et al. | Pregnancy after liver transplantation under tacrolimus. | 1997 | Transplantation | pmid:9293865 |
| Farid SG et al. | Alemtuzumab (Campath-1H)-induced coagulopathy in renal transplantation. | 2009 | Transplantation | pmid:19502974 |
| Garcia-Criado FJ et al. | Tacrolimus (FK506) down-regulates free radical tissue levels, serum cytokines, and neutrophil infiltration after severe liver ischemia. | 1997 | Transplantation | pmid:9293871 |
| Satterthwaite R et al. | Incidence of new-onset hypercholesterolemia in renal transplant patients treated with FK506 or cyclosporine. | 1998 | Transplantation | pmid:9484771 |
| Francavilla A et al. | Inhibition of liver, kidney, and intestine regeneration by rapamycin. | 1992 | Transplantation | pmid:1371198 |
| Sheikh AM et al. | Concomitant human immunodeficiency virus protease inhibitor therapy markedly reduces tacrolimus metabolism and increases blood levels. | 1999 | Transplantation | pmid:10440408 |
| Furukawa H et al. | Prolongation of canine liver allograft survival by a novel immunosuppressant, FTY720: effect of monotherapy and combined treatment with conventional drugs. | 2000 | Transplantation | pmid:10670633 |
| Asako H et al. | Reduction of leukocyte adherence and emigration by cyclosporine and L683,590 (FK506) in postcapillary venules. | 1992 | Transplantation | pmid:1384191 |
| Yun J et al. | Bilateral ischemic optic neuropathy in a patient using tacrolimus (FK506) after liver transplantation. | 2010 | Transplantation | pmid:20559109 |
| Yasunami Y et al. | FK506 as the sole immunosuppressive agent for prolongation of islet allograft survival in the rat. | 1990 | Transplantation | pmid:1691535 |
| Kato T et al. | Rhabdomyolysis after kidney transplantation caused by elevated serum cyclosporine due to metabolic enzyme and transporters disorder. | 2011 | Transplantation | pmid:21747275 |
| Pratschke J et al. | Treatment of cyclosporine-related adverse effects by conversion to tacrolimus after liver transplantation. | 1997 | Transplantation | pmid:9326428 |
| Ashokkumar C et al. | Allospecific CD154+ T-cytotoxic memory cells identify recipients experiencing acute cellular rejection after renal transplantation. | 2011 | Transplantation | pmid:21747326 |
| High KP | The antimicrobial activities of cyclosporine, FK506, and rapamycin. | 1994 | Transplantation | pmid:7517076 |
| Cosio FG et al. | Comparison of low versus high tacrolimus levels in kidney transplantation: assessment of efficacy by protocol biopsies. | 2007 | Transplantation | pmid:17318073 |
| Casey MJ et al. | Prolonged immunosuppression preserves nonsensitization status after kidney transplant failure. | 2014 | Transplantation | pmid:24717218 |
| Kahan BD | An immunosuppressive triumvirate to minimize renal injuries associated with calcineurin antagonist therapy. | 1999 | Transplantation | pmid:10428260 |
| Washburn K et al. | Steroid elimination 24 hours after liver transplantation using daclizumab, tacrolimus, and mycophenolate mofetil. | 2001 | Transplantation | pmid:11726831 |
| Moxey-Mims MM et al. | Increased incidence of insulin-dependent diabetes mellitus in pediatric renal transplant patients receiving tacrolimus (FK506) | 1998 | Transplantation | pmid:9521193 |
| Tzakis AG et al. | Alemtuzumab (Campath-1H) combined with tacrolimus in intestinal and multivisceral transplantation. | 2003 | Transplantation | pmid:12792506 |
| Hytiroglou P et al. | FK506 versus cyclosporine as primary immunosuppressive agent for orthotopic liver allograft recipients. Histologic and immunopathologic observations. | 1993 | Transplantation | pmid:7506452 |
| Gallon L et al. | Differential Effects of Calcineurin and Mammalian Target of Rapamycin Inhibitors on Alloreactive Th1, Th17, and Regulatory T Cells. | 2015 | Transplantation | pmid:25905982 |
| Alhamad T et al. | Targeting High Calcineurin Inhibitor Levels After Acute Rejection With Less Tremor: A New Strategy. | 2017 | Transplantation | pmid:28422926 |
| Jordan ML et al. | Long-term results of pancreas transplantation under tacrolius immunosuppression. | 1999 | Transplantation | pmid:10075592 |
| Khanna AK | Mechanism of the combination immunosuppressive effects of rapamycin with either cyclosporine or tacrolimus. | 2000 | Transplantation | pmid:10972232 |
| Koh A et al. | Supplemental islet infusions restore insulin independence after graft dysfunction in islet transplant recipients. | 2010 | Transplantation | pmid:20145529 |
| Shapiro R et al. | Pediatric renal transplantation under tacrolimus-based immunosuppression. | 1999 | Transplantation | pmid:10075598 |
| Sofi AA et al. | Bullous pemphigoid associated with acute renal allograft rejection. | 2010 | Transplantation | pmid:20145531 |
| Min DI et al. | Circadian variation of tacrolimus disposition in liver allograft recipients. | 1996 | Transplantation | pmid:8900327 |
| Jindal RM et al. | Diabetogenicity of FK506 versus cyclosporine in liver transplant recipients. | 1994 | Transplantation | pmid:7519799 |
| Mor E et al. | Reversal of severe FK506 side effects by conversion to cyclosporine-based immunosuppression. | 1994 | Transplantation | pmid:7519800 |
| Eckhoff DE et al. | Tacrolimus (FK506) and mycophenolate mofetil combination therapy versus tacrolimus in adult liver transplantation. | 1998 | Transplantation | pmid:9458011 |
| Murase N et al. | Hamster-to-rat heart and liver xenotransplantation with FK506 plus antiproliferative drugs. | 1993 | Transplantation | pmid:7682735 |
| Laskow DA et al. | An open-label, concentration-ranging trial of FK506 in primary kidney transplantation: a report of the United States Multicenter FK506 Kidney Transplant Group. | 1996 | Transplantation | pmid:8878381 |
| Mourad M et al. | Sirolimus and tacrolimus trough concentrations and dose requirements after kidney transplantation in relation to CYP3A5 and MDR1 polymorphisms and steroids. | 2005 | Transplantation | pmid:16249748 |
| Woodle ES et al. | Tacrolimus therapy for refractory acute renal allograft rejection: definition of the histologic response by protocol biopsies. | 1996 | Transplantation | pmid:8878382 |
| Macedo C et al. | Long-term effects of alemtuzumab on regulatory and memory T-cell subsets in kidney transplantation. | 2012 | Transplantation | pmid:22343334 |
| Tanaka A et al. | Living related liver transplantation across ABO blood groups. | 1994 | Transplantation | pmid:7522363 |
| Vincenti F et al. | A long-term comparison of tacrolimus (FK506) and cyclosporine in kidney transplantation: evidence for improved allograft survival at five years. | 2002 | Transplantation | pmid:11907427 |
| Klein A et al. | Impact of a pharmaceutical care program on liver transplant patients' compliance with immunosuppressive medication: a prospective, randomized, controlled trial using electronic monitoring. | 2009 | Transplantation | pmid:19300186 |
| Stevens C et al. | The effects of immunosuppressive agents on in vitro production of human immunoglobulins. | 1991 | Transplantation | pmid:1710843 |
| Beckebaum S et al. | Predictive factors of outcome in patients transplanted for hepatitis B. | 2009 | Transplantation | pmid:19300191 |
| Pascual J et al. | Authors' reply: cyclosporine A versus tacrolimus in steroid withdrawal strategies. | 2011 | Transplantation | pmid:21336083 |
| Langrehr JM et al. | Evidence that indefinite survival of small bowel allografts achieved by a brief course of cyclosporine or FK506 is not due to systemic hyporesponsiveness. | 1992 | Transplantation | pmid:1384185 |
| Nakajima K et al. | Prolongation of cardiac xenograft survival in rats treated with 15-deoxyspergualin alone and in combination with FK506. | 1988 | Transplantation | pmid:2454521 |
| Fredericks S and Holt DW | TGF-beta quantitation can be tricky. | 1999 | Transplantation | pmid:10480399 |
| Schvarcz R et al. | Interaction between nelfinavir and tacrolimus after orthoptic liver transplantation in a patient coinfected with HIV and hepatitis C virus (HCV). | 2000 | Transplantation | pmid:10852623 |
| Baggio B et al. | Relationship between plasma phospholipid polyunsaturated fatty acid composition and bone disease in renal transplantation. | 2005 | Transplantation | pmid:16314806 |
| Holman MJ et al. | FK506-associated thrombotic thrombocytopenic purpura. | 1993 | Transplantation | pmid:7678357 |
| Todo S et al. | Small intestinal transplantation in humans with or without the colon. | 1994 | Transplantation | pmid:7512291 |